France 2030 award winner: SGH recognized for its industrial Innovation in Healthcare

SGH Medical Pharma had the honor of being recognized as part of the France 2030 investment plan. During the awards ceremony held in the Isère department, our CEO, Jérôme Empereur, represented our group alongside other regional award winners, all committed to industrial transformation.

With 389 projects supported across the region, Isère is asserting itself more than ever as a major hub for industrial innovation. Our project, AMBITION DM 2025, was recognized as one of the key initiatives addressing issues of health sovereignty and technological independence.

An industrial capacity serving public health
Driven by our ambition to bring back critical activities to France, the AMBITION DM 2025 project is based on two main pillars:

• The installation and operational launch of an ISO8 cleanroom for the production of strategic components for the biotech and injectable markets.
• The extension of our existing site to accommodate these new industrial activities. With this project, the plant has also officially become a pharmaceutical establishment.

This project significantly strengthens our ability to produce strategic medical components in France, which are essential, in particular for biological testing and vaccination campaigns.

A distinction that confirms our direction
This recognition honors not only a major industrial project but also the vision carried by SGH Medical Pharma: to develop a medical industry prepared to meet future emergencies and transformation

We extend our thanks to all institutional stakeholders involved in the France 2030 framework: the French State, the Auvergne-Rhône-Alpes Region, the Isère department, and all our partners. Their trust is the foundation of this collective momentum.